Please login to the form below

Not currently logged in
Email:
Password:

GSK vaccines business management shift

Jean Stephenne has been appointed as chairman of GlaxoSmithKline (GSK) Biologicals as part of GSK's planned succession strategy

Jean Stephenne has been appointed as chairman of GlaxoSmithKline (GSK) Biologicals as part of GSK's planned succession strategy.

Mr Stephenne will assume his new position with immediate effect while continuing in his current role as president, GSK Biologicals. Over the next two years operational responsibility for GSK Biologicals will move to Dr Moncef Slaoui, who continues in his current role as chairman of research and development. 

CEO of GSK, Andrew Witty, commented: "Succession planning is fundamental to GSK's long-term success and today's changes are clear evidence that we are taking proactive steps to maintain excellent leadership in our business. Jean has built a world-leading vaccines business and as chairman will continue to be instrumental in driving forward our public health agenda, while Moncef has more than 17 years experience working in the vaccines area and has played a critical role in developing the strong pipeline we have today."

According to Mr Witty, these changes to the business will ensure a continued focus on development and delivery of GSK's vaccine pipeline.

15th March 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics